How to Watch the Full Moon Rise Alongside a Royal Star This Week

Adding to the sky show is Regulus, one of the brightest stars visible from Earth, and a beacon steeped in myth and prestige ...
Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Seeking Alpha

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction ...
Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with ...

SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
FierceBiotech

Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK

LA JOLLA, Calif., Nov. 3, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs ...
Seeking Alpha

The Read On Regulus Therapeutics

Today's in-depth piece is on microcap name that came as a suggestion for research from a Seeking Alpha follower. A full investment analysis follows below. The company seeks to develop and ...
Yahoo

Mercury makes an elusive appearance with the bright star Regulus on Sept. 2

When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: NASA/JHU-APL/Carnegie Institution of Washington Look to the east slightly ahead of dawn ...
FierceBiotech

RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by ...

-RG-125 (AZD4076) is Regulus' 3rd Clinical Candidate, Achieving Key 'Clinical Map Initiative' Goal for 2015- LA JOLLA, Calif., April 7, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a ...